Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01261299 · ClinicalTrials.gov registry record · Early Phase 1
Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer
A Early Phase 1 study, sponsored by University of California, Davis.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
NCT01261299 is a Early Phase 1 study that was terminated before completion, run by University of California, Davis. The registered enrollment target is 21 participants.
The verdict
NCT01261299, a Early Phase 1 study, was terminated before completion, sponsored by University of California, Davis.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Carboplatin kills cancer cells mainly through induction of DNA damage (drug-DNA adducts). The goal of this clinical trial is to determine if chemoresistance to carboplatin can be identified by measuring carboplatin-induced DNA monoadducts, the precursor of Pt-DNA diadducts or crosslinks, from subtherapeutic drug doses given prior to the initiation of chemotherapy. We hypothesize that low levels of carboplatin-DNA monoadducts and rapid drug-DNA adduct repair correlate with chemoresistance. A highly sensitive technology, called accelerator mass spectrometry (AMS), will be used to measure carboplatin-DNA monoadducts from patient samples. AMS can measure C-14 at the attomole level in specimens of milligram size. In this study, patients will receive one non-toxic "microdose" (defined as 1/100th the therapeutic dose) of C-14-labeled carboplatin. Blood specimens will be drawn for determination of carboplatin-DNA monoadduct formation and repair in peripheral blood mononuclear cells (PBMC), and pharmacokinetics (PK) will be determined from serum ultrafiltrate. In patients microdosed prior to providing tumor samples, a few milligrams of leftover tumor biopsy/resection specimens will be analyzed for formation of carboplatin-DNA monoadducts. Patients will subsequently receive carboplatin-based chemotherapy. The levels of microdose-induced carboplatin-DNA monoadducts will be correlated with response to chemotherapy. Some blood and biopsy samples will be assayed by RT-PCR for several putative resistance markers at the mRNA level. Side effects will also be monitored and compared to the AMS data. This trial will also utilize PK, DNA repair and pharmacogenomics data in order to determine some of the underlying chemoresistance mechanisms.
Interventions
- DRUG Carbon-14-labeled carboplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2010-12 |
| Est. Completion | 2016-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01261299
The ClinicalTrials.gov registry entry for NCT01261299 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Carbon-14-labeled carboplatin is the first listed.
NCT01261299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01261299 about?
NCT01261299 is a clinical study titled "Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer". Carboplatin kills cancer cells mainly through induction of DNA damage (drug-DNA adducts). The goal of this clinical trial is to determine if chemoresistance to carboplatin can be identified by measuring carboplatin-induced DNA monoadducts, the precursor of Pt-DNA diadducts or crosslinks, from subthe...
What is the current status of trial NCT01261299?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2010-12. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01261299?
The interventions under investigation include: Carbon-14-labeled carboplatin (DRUG).
Who is sponsoring clinical trial NCT01261299?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.